AR024242A1 - COMPUESTO HETEROBICICLO CON CONTENIDO DE NITROGENO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE , Y EL USO DE DICHOS COMPUESTOS EN LA FABRICACIoN DE UN MEDICAMENTO. - Google Patents

COMPUESTO HETEROBICICLO CON CONTENIDO DE NITROGENO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE , Y EL USO DE DICHOS COMPUESTOS EN LA FABRICACIoN DE UN MEDICAMENTO.

Info

Publication number
AR024242A1
AR024242A1 ARP990106759A ARP990106759A AR024242A1 AR 024242 A1 AR024242 A1 AR 024242A1 AR P990106759 A ARP990106759 A AR P990106759A AR P990106759 A ARP990106759 A AR P990106759A AR 024242 A1 AR024242 A1 AR 024242A1
Authority
AR
Argentina
Prior art keywords
compounds
manufacture
heterobiciclo
compound
pharmaceutical composition
Prior art date
Application number
ARP990106759A
Other languages
English (en)
Inventor
Karen A Rossi
Joseph Cacciola
James R Pruitt
Donald J Pinto
Charles G Clark
Patrick Y S Lam
John M Fevig
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR024242(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of AR024242A1 publication Critical patent/AR024242A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuetos heterobiciclos con contenido de nitrogeno seleccionados del grupo que consiste del grupo de formulas que figura abajo, o un estereoisomero o unasal aceptable para uso farmacéutico del mismo, donde los sustituyentes son aquellos que están descriptos en la memoria descriptiva y reivindicaciones. Tambiénse mencionan las composiciones farmacéuticas que los comprenden, un método para tratar o prevenir afecciones tromboembolicas y el uso de dichos compuestos enla fabricacion de medicamentosutiles para tratar afecciones tromboembolicas y sus derivados o formas de sal aceptable para uso farmacéutico de los mismos, queson utiles como inhibidores del factor Xa.
ARP990106759A 1998-12-23 1999-12-23 COMPUESTO HETEROBICICLO CON CONTENIDO DE NITROGENO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE , Y EL USO DE DICHOS COMPUESTOS EN LA FABRICACIoN DE UN MEDICAMENTO. AR024242A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11362898P 1998-12-23 1998-12-23
US12763399P 1999-04-02 1999-04-02

Publications (1)

Publication Number Publication Date
AR024242A1 true AR024242A1 (es) 2002-09-25

Family

ID=26811284

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106759A AR024242A1 (es) 1998-12-23 1999-12-23 COMPUESTO HETEROBICICLO CON CONTENIDO DE NITROGENO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE , Y EL USO DE DICHOS COMPUESTOS EN LA FABRICACIoN DE UN MEDICAMENTO.

Country Status (26)

Country Link
US (2) US6413980B1 (es)
EP (1) EP1140941B1 (es)
JP (1) JP2002533465A (es)
KR (1) KR100628407B1 (es)
CN (1) CN100340559C (es)
AR (1) AR024242A1 (es)
AT (1) ATE280171T1 (es)
AU (1) AU759711B2 (es)
BR (1) BR9917080A (es)
CA (1) CA2349330C (es)
DE (1) DE69921358T2 (es)
DK (1) DK1140941T3 (es)
EA (1) EA004515B1 (es)
ES (1) ES2232202T3 (es)
HK (1) HK1052508B (es)
HR (1) HRP990396A2 (es)
IL (2) IL142959A0 (es)
MX (1) MXPA01006502A (es)
MY (1) MY138239A (es)
NO (1) NO319816B1 (es)
NZ (1) NZ511674A (es)
PT (1) PT1140941E (es)
SI (1) SI1140941T1 (es)
TW (1) TWI225862B (es)
WO (1) WO2000039131A1 (es)
ZA (1) ZA200103795B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268712A1 (en) 2000-06-23 2002-01-08 Bristol-Myers Squibb Company 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor Xa inhibitors
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (en) 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US6960595B2 (en) * 2001-03-23 2005-11-01 Bristol-Myers Squibb Pharma Company 5-6 to 5-7 Heterobicycles as factor Xa inhibitors
US6750225B2 (en) 2001-04-18 2004-06-15 Bristol-Myers Squibb Pharms Company 1,4,5,6-tetrahydropyrazolo-[3,4,-c]-pyridin-7-ones useful as factor Xa inhibitors
CA2441772A1 (en) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-¬3,4-c|-pyridin-7-ones as factor xa inhibitors
EP1414449A4 (en) * 2001-05-22 2005-04-06 Bristol Myers Squibb Co FACTOR XA BICYCLIC INHIBITORS
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
EP1427415B1 (en) 2001-09-21 2009-08-12 Brystol-Myers Squibb Company Lactam-containing compounds and derivatives thereof as factor xa inhibitors
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
WO2003048081A2 (en) * 2001-12-04 2003-06-12 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
TW200303201A (en) 2001-12-10 2003-09-01 Bristol Myers Squibb Co Synthesis of 4,5-dihydro-pyrazolo [3,4-c] pyrid-2-ones
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
EP1482931B1 (en) 2002-03-05 2011-10-19 TransTech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
AU2003273179A1 (en) 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
BR0317659A (pt) * 2002-12-23 2005-12-06 Aventis Pharma Gmbh Derivados de pirazol como inibidores de fator xa
US7122557B2 (en) * 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
CN1805743A (zh) * 2003-05-20 2006-07-19 特兰斯泰克制药公司 用作逆转淀粉样变性及其他与之相关疾病的rage拮抗剂
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
AU2004276341B2 (en) 2003-09-23 2011-04-14 Vertex Pharmaceuticals Incorporated Pyrazolopyrrole derivatives as protein kinase inhibitors
EP2910125B1 (en) 2004-02-24 2018-05-02 Sumitomo Chemical Company, Limited Insecticide compositions
BRPI0514390A (pt) 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7381732B2 (en) * 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
MX2007008290A (es) 2005-01-07 2008-02-15 Synta Pharmaceuticals Corp Compuestos para inflamacion y usos inmuno-relacionados.
CA2669311C (en) * 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
JP5352449B2 (ja) 2007-04-18 2013-11-27 キッセイ薬品工業株式会社 縮合へテロ環誘導体、それを含有する医薬組成物及びその医薬用途
EP2145889A4 (en) 2007-04-18 2012-04-18 Kissei Pharmaceutical HETEROCYCLIC FUSED CORE DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE DERIVATIVE, AND USE OF THE COMPOSITION FOR MEDICAL PURPOSES
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
SMT201900650T1 (it) 2010-02-25 2020-01-14 Pfizer Formulazioni di apixaban
JP2014516072A (ja) 2011-06-10 2014-07-07 ディフアルマ フランチス ソシエタ ア レスポンサビリタ リミタータ アピキサバン製造方法
CN104109165A (zh) * 2013-04-19 2014-10-22 四川海思科制药有限公司 4,5-二氢-吡唑并[3,4-c]吡啶-2-酮衍生物、其制备方法以及应用
CN103992310B (zh) * 2013-05-14 2016-07-06 中国医学科学院医药生物技术研究所 一组取代苯并杂环胺衍生物及其制备方法和作为impdh抑制剂的相关应用
CN104395312B (zh) * 2013-06-21 2016-04-27 四川海思科制药有限公司 4,5-二氢吡唑并[3,4-c]吡啶-2-酮的螺环衍生物、其制备方法以及应用
EP3019481B1 (de) 2013-07-08 2019-03-06 Bayer CropScience Aktiengesellschaft Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel
CN105745212B (zh) * 2013-12-06 2017-09-12 四川海思科制药有限公司 取代的4,5‑二氢吡唑并[3,4‑c]吡啶‑2‑酮的螺环衍生物及应用
WO2015162551A1 (en) 2014-04-21 2015-10-29 Mylan Laboratories Ltd Process for the preparation of apixaban
CN105085515B (zh) * 2014-05-22 2019-02-01 华北制药股份有限公司 作为凝血因子Xa抑制剂的酰肼类化合物
WO2015176625A1 (zh) * 2014-05-22 2015-11-26 南京明德新药研发股份有限公司 作为凝血因子Xa抑制剂的酰肼类化合物
CN105384739B (zh) * 2014-09-02 2020-03-20 石药集团中奇制药技术（石家庄）有限公司 吡唑并[3,4-c]吡啶类衍生物
WO2016035007A2 (en) 2014-09-05 2016-03-10 Unichem Laboratories Limited An improved process for the preparation of apixaban and intermediates thereof
CN104311574B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 含有噻唑的吡唑并哌啶酮类化合物及其组合物及用途
CN104277037B (zh) * 2014-09-19 2015-12-09 广东东阳光药业有限公司 含有螺环的吡唑并哌啶酮类化合物及其组合物及用途
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311555B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
CN104311575B (zh) * 2014-09-19 2016-04-20 广东东阳光药业有限公司 含有稠环的吡唑并哌啶酮类化合物及其组合物及用途
CN104311557B (zh) * 2014-09-19 2016-01-06 广东东阳光药业有限公司 含有二酮取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104311556B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有环氧烷基取代基的吡唑并哌啶酮类化合物及其组合物及用途
CN104530029B (zh) * 2014-12-09 2017-04-12 广东东阳光药业有限公司 作为Xa因子抑制剂的杂环化合物及其使用方法和用途
CN104513239B (zh) * 2014-12-10 2017-08-22 沈阳药科大学 吡唑并[3,4‑c]吡啶‑7‑酮类化合物及其应用
US10077263B2 (en) 2016-04-29 2018-09-18 Optimus Drugs Private Limited Process for the preparation of Apixaban
WO2018150286A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Pharmaceutical composition of apixaban
CN107235986B (zh) * 2017-05-27 2019-04-12 华南师范大学 一种合成氮氧杂桥联唑啉化合物的方法
GB201807014D0 (en) 2018-04-30 2018-06-13 Univ Leeds Innovations Ltd Factor xlla inhibitors
AU2019339777B2 (en) 2018-09-12 2022-09-01 Novartis Ag Antiviral pyridopyrazinedione compounds
KR102128509B1 (ko) 2018-12-19 2020-07-01 한국과학기술연구원 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
US11667613B2 (en) 2019-09-26 2023-06-06 Novartis Ag Antiviral pyrazolopyridinone compounds
PL3946277T3 (pl) 2019-11-13 2025-10-06 Unison Pharmaceuticals Pvt. Ltd. Rozpadające się w jamie ustnej farmaceutyczne kompozycje apiksabanu
GB202107722D0 (en) 2021-05-28 2021-07-14 Lunac Therapeutics Ltd Factor XIIA Inhibitors
CN113956248B (zh) * 2021-11-12 2023-07-04 贵州中医药大学 一种具有抗炎作用的化合物衍生物及其制备方法和应用
AR127646A1 (es) 2021-11-12 2024-02-14 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
TW202530200A (zh) * 2023-09-25 2025-08-01 大陸商上海濟煜醫藥科技有限公司 嗒𠯤酮類化合物作為泛素－特異性蛋白酶１抑制劑的製備方法、應用及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340269A (en) * 1964-09-08 1967-09-05 Ciba Geigy Corp 1-substituted 4-acyl-2, 3-dioxo-piperidine
US3365459A (en) * 1964-09-08 1968-01-23 Ciba Geigy Corp Certain tetrahydro pyrazolo-pyridine and pyrazolo-piperidine derivatives
US3423414A (en) * 1966-01-13 1969-01-21 Ciba Geigy Corp Pyrazolopyridines
US3939161A (en) * 1973-10-29 1976-02-17 Abbott Laboratories 1,3-Dimethyl- 1H-pyrazolo(4,3-D) pyrimidine-7 (6H)-ones
JPS5721388A (en) * 1980-07-11 1982-02-04 Nippon Nohyaku Co Ltd Condensed pyrazole derivative
JPS63145282A (ja) * 1986-12-08 1988-06-17 Taiyo Yakuhin Kogyo Kk ピリダジン誘導体
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
EP0557526B8 (en) * 1991-08-07 2003-08-13 Daiichi Suntory Pharma Co., Ltd. Pyrroloazepine compound
WO1994020460A1 (en) 1993-03-11 1994-09-15 Smithkline Beecham Corporation Chemical compounds
AU695301B2 (en) * 1993-07-06 1998-08-13 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines
EP0787132A1 (en) * 1994-10-20 1997-08-06 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AU1345697A (en) * 1995-12-22 1997-07-17 Du Pont Merck Pharmaceutical Company, The Novel integrin receptor antagonists
EP0807633B1 (en) * 1996-05-15 2002-11-06 Pfizer Inc. Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
FR2750862B1 (fr) * 1996-07-12 1998-10-16 Dupin Jean Pierre Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
JP2002507996A (ja) * 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
AU3110999A (en) * 1998-03-27 1999-10-18 Du Pont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
DE19845153A1 (de) 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
DE19900471A1 (de) 1999-01-08 2000-07-13 Merck Patent Gmbh Imidazo[4,5c]-pyridin-4-on-derivate
JP2003509412A (ja) 1999-09-17 2003-03-11 シーオーアール セラピューティクス インコーポレイテッド Ｘａ因子阻害剤

Also Published As

Publication number Publication date
EA200100688A1 (ru) 2001-12-24
MXPA01006502A (es) 2002-04-08
TWI225862B (en) 2005-01-01
IL142959A (en) 2010-05-31
EP1140941A1 (en) 2001-10-10
HK1052508A1 (zh) 2003-09-19
US20030004167A1 (en) 2003-01-02
BR9917080A (pt) 2002-03-12
JP2002533465A (ja) 2002-10-08
NZ511674A (en) 2003-11-28
ES2232202T3 (es) 2005-05-16
NO319816B1 (no) 2005-09-19
CA2349330C (en) 2009-09-29
KR100628407B1 (ko) 2006-09-26
DK1140941T3 (da) 2005-02-14
NO20013072D0 (no) 2001-06-20
KR20010092754A (ko) 2001-10-26
MY138239A (en) 2009-05-29
SI1140941T1 (en) 2005-04-30
DE69921358D1 (de) 2004-11-25
AU759711B2 (en) 2003-04-17
US6413980B1 (en) 2002-07-02
EP1140941B1 (en) 2004-10-20
US6673810B2 (en) 2004-01-06
CN100340559C (zh) 2007-10-03
HRP990396A2 (en) 2000-08-31
DE69921358T2 (de) 2006-03-09
CN1391575A (zh) 2003-01-15
ATE280171T1 (de) 2004-11-15
NO20013072L (no) 2001-06-20
EA004515B1 (ru) 2004-04-29
CA2349330A1 (en) 2000-07-06
IL142959A0 (en) 2002-04-21
HK1052508B (zh) 2008-08-01
ZA200103795B (en) 2002-08-12
AU2371700A (en) 2000-07-31
WO2000039131A1 (en) 2000-07-06
PT1140941E (pt) 2005-02-28

Similar Documents

Publication Publication Date Title
AR126914A1 (es) Inhibidores de ras novedosos
AR003455A1 (es) Derivados tetraciclicos, su uso en la preparacion de un medicamento, un metodo de tratamiento, una composicion farmaceutica y procesos para lapreparacion de una composicion farmaceutica y para preparar los compuestos.
AR126701A1 (es) Derivados de n-ciclopropilpirido[4,3-d]pirimidin-4-amina y usos de los mismos
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
UY27882A1 (es) Compuestos quimicos
AR029806A1 (es) Derivados de fenilo, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de la composicion farmaceutica y usos de estos derivados
PE20191613A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CL2004000849A1 (es) Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
CO2026002343A2 (es) Inhibidores de pi3k
ES2059207T3 (es) Procedimiento para la preparacion de derivados del taxano, nuevos derivados obtenidos y composiciones farmaceuticas que les contienen.
RU94039542A (ru) Производные пиперазина как антагонисты 5-нт-рецепторов, способ получения, фармацевтическая композиция
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
AR047070A1 (es) Derivados de difenilazetidona
BRPI0415437A (pt) composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
UY28691A1 (es) Derivados de difenilazetidona
ECSP045073A (es) Nuevos derivados de piperazina
BR112019021853A2 (pt) Compostos de inibidor de vmat2 e composições dos mesmos
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BRPI0406717A (pt) Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
UY26564A1 (es) Inhibidores del factor xa con aril - amidinas y sus derivados, y composiciones farmacéuticas que contienen los mismos

Legal Events

Date Code Title Description
FG Grant, registration